Skip to main content

Advertisement

Table 4 Hazard Ratios by HPV-16 E6/E7 baseline status and change in OD ratio at last follow-up

From: Human papillomavirus serologic follow-up response and relationship to survival in head and neck cancer: a case-comparison study

Outcome/Antibody Status HPV-16 E6 HPV-16 E7 HPV-16 E6 and/or E7
  n (%) HR (95% CI)1 p-value2 n (%) HR (95% CI)1 p-value2 n (%) HR (95% CI)1 p-value2
Overall Deaths    0.01    0.04    0.01
   Negative 353 (40.2) 4.6 (1.4-15.3)   344 (38.2) 3.0 (1.03-8.5)   344 (41.0) 3.8 (1.3-11.0)  
   Positive 3 (13.6) 1.0   4 (20.0) 1.0   4 (15.8) 1.0  
No OD decrease 0    0    0   
OD Decrease 35    45    45   
Disease Specific Deaths    0.017    0.07    0.04
   Negative 196 (24.4) NE3   188 (22.5) 6.4 (0.8-48.7)   188 (24.3) 8.4 (1.1-63.3)  
   Positive 0 (0.0) 1.0   1 (5.6) 1.0   1 (4.2) 1.0  
No OD decrease 0    0    0   
OD Decrease 0    15    15   
Recurrence    0.35    0.36    0.90
   Negative 178 (21.5) 2.1 (0.4-9.7)   174 (21.0) 2.0 (0.4-9.4)   159 (20.0) 1.1 (0.3-3.5)  
   Positive 2 (9.1) 1.0   2 (10.0) 1.0   4 (15.4) 1.0  
No OD decrease 15    0    25   
OD Decrease 1    210    210   
  1. 1Adjusted for continuous age and stage; 2Adjusted p-value from Cox Regression models; 3Tumor status: 3 HPV-16, 1 HPV-33, 27 HPV-; 4Tumor status: 2 HPV-16, 1 HPV-33, 27 HPV-; 5Tumor status: all HPV-16; 6Tumor status: 2 HPV-16, 18 HPV-; 7Not estimable, Kaplan-Meier log-rank p = 0.01; 8Tumor status: 1 HPV-16, 1 HPV-33, 14 HPV-; 9Tumor status: 1 HPV-33, 13 HPV-; 10Tumor status: 1 HPV-16, 1 HPV-.